Recursion's CEO outlines a two-pronged pipeline strategy. The first prong uses phenomics to uncover novel biological insights for new targets, like their FAP program. The second uses their AI-driven small molecule design platform to improve the therapeutic index for known but historically 'hard-to-drug' targets, like CDK7. This balanced portfolio approach de-risks development by leveraging different strengths of their end-to-end platform.

To build investor confidence in the high-risk neuroscience field, Neurocrine employs a dual strategy. It highlights its own proven track record while simultaneously de-risking its pipeline by targeting biological pathways already validated by competitors, aiming to create superior, best-in-class medicines rather than pursuing unproven science.

Unlike traditional biotechs seeking pharma validation, Xaira's initial collaborations will be with tech companies for AI tools, lab automation, and compute. This reflects a strategy focused on building the core R&D engine first, seeking partners that accelerate platform development rather than provide capital.

By identifying as an AI company developing medicines, Xaira re-frames its narrative. This justifies the massive upfront capital needed to build a fully integrated ML R&D platform before generating a traditional drug pipeline, a model that would not fit a standard biotech seed round.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

The company's R&D strategy pragmatically filters for targets that are not only highly validated and accessible with its current technology, but are also already on the radar of potential big pharma partners ("strategics"), indicating a clear market and potential exit path.

ProPhet's strategy is to focus on 'hard-to-drug' proteins, which are often avoided because they lack the structural data required for traditional discovery. Because ProPhet's AI model needs very little protein information to predict interactions, this data scarcity becomes a competitive advantage.

For a heavily capitalized AI-platform company like Xaira, the impetus for new funding is not a typical clinical milestone. Instead, it is the opportunity to expand its core design engine into new drug modalities, like small molecules, that were outside the scope of the original billion-dollar plan.